Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease (NAFLD)Using Liver Biopsy as Reference.

NCT01985009 is registered in ClinicalTrials.gov with Echosens as lead sponsor.

NCT NCT01985009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01985009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease (NAFLD)Using Liver Biopsy as Reference.
Lead sponsor
Echosens
Phase
Not applicable
Overall status
Completed
Start date
January 31, 2014
Completion date
January 17, 2017
Enrollment
450 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic fatty liver disease